<DOC>
	<DOCNO>NCT00857818</DOCNO>
	<brief_summary>The purpose study determine whether patient schizophrenia , schizoaffective disorder , bipolar I disorder also metabolic syndrome large decrease fast non-high density lipoprotein ( non-HDL ) cholesterol level aripiprazole current atypical antipsychotic treatment ( olanzapine , risperidone , quetiapine ) .</brief_summary>
	<brief_title>Trial Comparing Effects Aripiprazole With Those Standard Care Non-HDL Cholesterol Patients With Schizophrenia Bipolar I Disorder Who Have Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Competency understanding nature study ability sign inform consent form A clinical diagnosis schizophrenia , schizoaffective disorder , bipolar I disorder ( manic mixed ) treat antipsychotic ( oral olanzapine , risperidone quetiapine ) least 3 month . Treatment antipsychotic medication olanzapine , risperidone , quetiapine least 3 month A Clinical Global ImpressionSeverity Scale score 4 low baseline Confirmed diagnosis metabolic syndrome Patients receive treatment specifically parameter related metabolic syndrome time randomization Women childbearing potential must use adequate method contraception avoid pregnancy throughout study 4 week last dose investigational product Patients clinically appropriate switch current atypical antipsychotic aripiprazole ( determined investigator ) Risk suicide ( suicidal ideation recently attempt suicide ) Meeting Diagnostic Statistical Manual Mental Disorders , 4th ed , text revision criterion significant psychoactive substance use disorder within 3 month screen Diagnosis type 1 2 diabetes mellitus Current treatment 1 component metabolic syndrome Use medication purpose weight loss Diagnosis bipolar disorder bipolar 1 , depression psychotic symptom , organic brain syndrome History neuroleptic malignant syndrome Diagnosis Parkinson 's disease , Alzheimer 's disease , multiple sclerosis , cerebral palsy , epilepsy , mental retardation History seizures Abnormal blood count platelet , hemoglobin , absolute neutrophil , aspartate aminotransferase , alanine aminotransferase , creatinine , fast glucose , thyroidstimulating hormone Electrocardiogram recording QTc interval &gt; 475 msec Detectable level cocaine positive screen stimulant drug consider ( determined investigator ) abuse dependence Blood alcohol level superior equal 50 mg/dL [ 10.9 mmol/L ] Prior participation aripiprazole clinical trial Treatment aripiprazole within 1 month enrollment Predefined exclusionary laboratory test Patients Bipolar Disorder treat adjunctive therapy stable dose mood stabilizer ( lithium valproate ) must undergo 30day washout period adjunctive therapy , antidepressant , prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>